Volume-2 ,Issue-9, September- 2026

The study was designed to formulate Repaglinide-loaded Nanostructured Lipid Carriers (NLCs) and assess their ability to improve the drug's solubility and dissolution characteristics, with the ultimate aim of enhancing its oral delivery potential. Five formulations of Repaglinide-loaded NLCs (F1-F5) were developed by employing a combination of hot homogenization and ultrasonication. Compritol 888 ATO and Miglyol 812 were selected as the solid and liquid lipid components, respectively, while different concentrations and ratios of surfactants were investigated. Following optimization, the selected NLC formulation was lyophilized and converted into a tablet dosage form. The optimized formulation was further subjected to accelerated stability testing. Pre-formulation characterization established the identity and purity of Repaglinide and confirmed its lipophilic nature, as indicated by a log P value of 2.56. Comparative evaluation of the prepared NLCs identified F5 as the most promising formulation. F5 produced nanoparticles with a mean particle size of 79.3 ± 1.6 nm and a polydispersity index of 0.182, reflecting a relatively uniform particle-size distribution. The formulation exhibited a zeta potential of −31.2 ± 0.8 mV and achieved an entrapment efficiency of 92.1 ± 1.2%. The tablet prepared from F5 demonstrated markedly improved in-vitro drug release, reaching 95.4 ± 2.0% within 60 min, whereas the marketed conventional tablet exhibited only 64.2% release over the same period. The developed Repaglinide NLC system demonstrated substantial improvement in drug entrapment and dissolution performance compared with the conventional marketed formulation. Formulation F5, in particular, showed favorable nanoscale characteristics, high entrapment efficiency, enhanced drug release, and satisfactory stability. These findings support the potential of NLC technology as an effective lipid-based strategy for improving the oral delivery of Repaglinide and may contribute to improved therapeutic performance in Type 2 Diabetes Mellitus.

Keyword: Repaglinide, Nanostructured Lipid Carriers (NLCs), Type 2 Diabetes Mellitus, In-vitro Dissolution